Quest Diagnostics (DGX) has had a notable period of price momentum and has set fresh 1-year highs. The company's shares continue to see a surge, fueled by strong revenue growth and promising upside potential. Key company movements include the appointment of Benjamin Beauvalot as Senior Vice President and strategy and merger and acquisitions (M&A) officer following a series of strategically executed deals. The organization has actively been presenting at leading global healthcare conferences. DGX's financials highlight strong balance sheets and cash flows. A significant development includes the industry-first collaboration with Epic to enhance laboratory testing experiences. Brokerages have given DGX a moderate buy recommendation. The share outlook for 2026 appears promising following strong recent results, proposed buybacks, and the introduction of a new myeloma test. Investors are also responding favorably towards DGX's earnings beat, higher dividends and expansion plans, which are reflected in regulatory filings. This culmination of factors has boosted Quest Diagnostics SVP's holdings. Other strategic moves include the completion of a laboratory joint venture transaction with Corewell Health in Michigan and an agreement with Insight Molecular Diagnostics. This, along with a fascinating new Myeloma MRD blood test, promising Q3 2025 earnings, and forecasted upside potential, indicated that DGX remains an appealing investment.
Quest Diagnostics DGX News Analytics from Wed, 25 Jun 2025 07:00:00 GMT to Sat, 28 Feb 2026 11:31:46 GMT -
Rating 8
- Innovation 3
- Information 8
- Rumor -2
